Masakazu Toi Selected Research

Trastuzumab (Herceptin)

10/2022	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
9/2022	Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
8/2021	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).
3/2021	Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity.
1/2021	Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
1/2021	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
1/2021	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
7/2020	Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
2/2020	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
1/2020	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masakazu Toi Research Topics

Disease

279	Breast Neoplasms (Breast Cancer) 10/2022 - 01/2002
161	Neoplasms (Cancer) 10/2022 - 01/2002
23	Neoplasm Metastasis (Metastasis) 06/2021 - 11/2002
19	Neutropenia 01/2022 - 01/2002
13	Disease Progression 09/2022 - 01/2002
12	Carcinoma (Carcinomatosis) 07/2018 - 03/2003
9	Triple Negative Breast Neoplasms 01/2022 - 01/2013
7	Diarrhea 01/2022 - 09/2017
6	Leukopenia 09/2021 - 01/2002
5	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2022 - 01/2011
5	Fatigue 01/2021 - 01/2003
5	Hypoxia (Hypoxemia) 01/2020 - 10/2003
5	Carcinogenesis 11/2018 - 10/2002
4	Lymphatic Metastasis 01/2021 - 11/2002
4	Nausea 01/2020 - 10/2007
4	Febrile Neutropenia 05/2018 - 10/2007
3	Stomatitis 11/2017 - 05/2014
3	Residual Neoplasm 10/2016 - 03/2012
2	Hypertension (High Blood Pressure) 01/2022 - 09/2013
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 01/2018

Drug/Important Bio-Agent (IBA)

60	Hormones (Hormone)IBA 10/2022 - 04/2002
43	Trastuzumab (Herceptin)FDA Link 10/2022 - 01/2004
35	Estrogen ReceptorsIBA 05/2022 - 09/2002
30	ErbB Receptors (EGF Receptor)IBA 10/2022 - 07/2009
25	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2004
21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2020 - 03/2003
19	Proteins (Proteins, Gene)FDA Link 07/2018 - 01/2002
18	Aromatase InhibitorsIBA 01/2022 - 10/2002
18	Biological ProductsIBA 01/2022 - 05/2003
17	human ERBB2 proteinIBA 10/2022 - 03/2007
17	abemaciclibIBA 01/2022 - 09/2017
17	Docetaxel (Taxotere)FDA Link 07/2021 - 01/2003
15	taxaneIBA 10/2022 - 11/2007
15	Pharmaceutical PreparationsIBA 05/2020 - 10/2002
14	Fluorouracil (Carac)FDA LinkGeneric 06/2020 - 04/2002
13	AnthracyclinesIBA 10/2022 - 08/2004
13	palbociclibIBA 12/2021 - 12/2015
13	Tamoxifen FDA LinkGeneric 09/2010 - 01/2002
12	Letrozole (Femara)FDA LinkGeneric 04/2021 - 03/2005
11	Fulvestrant (Faslodex)FDA Link 05/2022 - 09/2017
11	Capecitabine (Xeloda)FDA Link 01/2022 - 03/2002
11	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2002
11	Progesterone Receptors (Progesterone Receptor)IBA 06/2021 - 09/2002
10	pertuzumabIBA 10/2022 - 01/2017
10	Epirubicin (Ellence)FDA LinkGeneric 04/2020 - 02/2004
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 03/2002
10	Estrogens (Estrogen)FDA Link 11/2018 - 01/2002
10	Aromatase (CYP19)IBA 05/2011 - 07/2002
9	exemestane (Aromasin)FDA Link 09/2019 - 07/2002
8	Phenobarbital (Luminal)FDA Link 10/2022 - 09/2010
8	Ado-Trastuzumab EmtansineIBA 10/2022 - 01/2017
8	eribulin FDA Link 09/2022 - 09/2017
8	Lapatinib (GW572016)FDA Link 08/2021 - 07/2009
7	Indocyanine Green (Cardio-Green)FDA LinkGeneric 11/2018 - 04/2010
7	Zoledronic Acid (Zometa)FDA Link 04/2018 - 12/2009
6	Cyclin-Dependent Kinase 4IBA 12/2021 - 09/2017
6	Messenger RNA (mRNA)IBA 07/2018 - 02/2002
6	Transcription Factors (Transcription Factor)IBA 01/2018 - 11/2004
5	Bevacizumab (Avastin)FDA Link 01/2022 - 03/2012
5	Vinorelbine (Navelbine)FDA LinkGeneric 07/2021 - 06/2005
5	Everolimus FDA Link 01/2019 - 05/2014
5	Indicators and Reagents (Reagents)IBA 06/2008 - 04/2002
5	EnzymesIBA 10/2007 - 02/2002
5	Thymidine PhosphorylaseIBA 03/2005 - 02/2002
4	Taxoids (Taxanes)IBA 10/2022 - 06/2005
4	Epidermal Growth Factor (EGF)IBA 01/2020 - 07/2011
4	Tumor Biomarkers (Tumor Markers)IBA 11/2019 - 04/2004
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2018 - 01/2002
4	Diphosphonates (Bisphosphonates)IBA 04/2018 - 05/2013
4	IsoflavonesIBA 11/2013 - 11/2005
4	Celecoxib (Celebrex)FDA Link 03/2013 - 09/2003
4	Angiogenesis InhibitorsIBA 01/2012 - 09/2003
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2006 - 09/2003
4	doxifluridineIBA 02/2005 - 03/2002
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 01/2018
3	CytokinesIBA 01/2019 - 02/2011
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 08/2004
3	Protein Isoforms (Isoforms)IBA 12/2018 - 01/2002
3	Estradiol (Delestrogen)FDA LinkGeneric 06/2018 - 01/2002
3	TabletsIBA 01/2018 - 01/2016
3	Coloring Agents (Dyes)IBA 12/2017 - 07/2013
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 03/2007 - 03/2002
3	Vascular Endothelial Growth Factor CIBA 03/2006 - 02/2004
3	NF-kappa B (NF-kB)IBA 11/2005 - 02/2005
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 07/2021 - 06/2018
2	Anastrozole (Arimidex)FDA LinkGeneric 04/2021 - 02/2012
2	Granzymes (Granzyme)IBA 03/2021 - 08/2015
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 06/2020

Therapy/Procedure

136	Therapeutics 09/2022 - 01/2002
53	Drug Therapy (Chemotherapy) 09/2022 - 11/2002
35	Neoadjuvant Therapy 10/2022 - 08/2004
9	Radiotherapy 01/2022 - 03/2012
9	Adjuvant Chemotherapy 01/2022 - 03/2003
8	Segmental Mastectomy (Lumpectomy) 01/2022 - 01/2005
6	Drug Tapering 01/2022 - 01/2002
6	Immunotherapy 05/2019 - 09/2003
4	Chemoprevention 11/2009 - 10/2002
3	Retreatment 09/2022 - 01/2018
3	Aftercare (After-Treatment) 01/2018 - 04/2010
2	Time-to-Treatment 05/2022 - 01/2018